思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 2025年5月15日 ，糖 尿病护理公司 Senseonics Holdings （NYSE: SENS） 宣布，启动一项约 5000万美元的普通股公开发行 计划 ，并同步与全球医疗健康公司 雅培 （Abbott） 达成 2500万美元的私募配售协议 ，合计 募资7500万美元（约合5.4亿人民币） 。 本轮交易旨在为公司核心产品 Eversense 365 连续血糖监测（CGM）系 统的全球商 业化、技术迭代以及运营扩展提供资金支持。 Senseonics表示，此次融资为公司下一阶段的发展提供关键资源，并进一步深化与雅培在糖尿病管理领域的战略合作。 # 融 资 结构与用 途 本次公开发行由 BTIG, LLC 担任独家账簿管理人，Senseonics 将通过 SEC Regulation A 规则以市场价格发行普通股，预计募集总额为 5000万美元 （扣除费用前）。 公司同时 ...

GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 100,000,000 shares of common stock at a price to the public of $0.50 per share of common stock. The gross proceeds to Senseonics from the offering, before deducting underwriting ...

Core Viewpoint - Senseonics Holdings, Inc. is set to release its first quarter 2025 financial results on May 8, 2025, after market close, indicating ongoing developments in its financial performance and product offerings [1]. Group 1: Financial Results Announcement - The company will announce its first quarter 2025 financial results after market close on May 8, 2025 [1]. - A conference call to discuss the financial performance will take place at 4:30 p.m. (Eastern Time) on the same day, which will also be available via webcast [2]. Group 2: Company Overview - Senseonics is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes management [3]. - The company's CGM systems, Eversense 365 and Eversense E3, feature a small sensor that is implanted under the skin and communicates with a smart transmitter, sending glucose data to a mobile app every 5 minutes [3].

Core Insights - Sequel Med Tech and Senseonics have announced a commercial development agreement to integrate the twiist Automated Insulin Delivery (AID) System with Senseonics' Eversense 365 CGM system, making it the first AID system compatible with a one-year CGM [2][3][5] - The integration aims to enhance diabetes management for individuals with type 1 diabetes by providing more tools for glucose control, convenience, and personalization [3][5] - The twiist AID System is designed to automatically adjust insulin delivery based on real-time sensor readings, offering flexibility in diabetes management [6][8] Company Overview - Sequel Med Tech is focused on developing innovative insulin delivery technologies and aims to simplify disease management through advanced systems [8] - Senseonics specializes in long-term implantable glucose monitoring systems, with the Eversense 365 being the only implantable CGM that offers continuous monitoring for up to one year [9][11] - The collaboration between Sequel and Senseonics represents a significant advancement in diabetes care, providing users with a comprehensive solution that combines advanced pump, algorithm, and sensor technologies [4][5] Product Details - The twiist AID System is FDA-cleared for individuals aged six and up with type 1 diabetes, allowing for precise insulin delivery tailored to individual needs [6] - Eversense 365 received FDA clearance as an integrated continuous glucose monitoring system, enabling its use within automated insulin delivery systems [5][10] - The integration of twiist and Eversense 365 is expected to be commercially available in Q3 2025, enhancing the options available for diabetes management [5][6]

Senseonics Holdings, Inc. (NYSE:SENS) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Brian Hansen - President of CGM at Ascensia Diabetes Care Rick Sullivan - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Matt Taylor - Jefferies Marie Thibault - BTIG Operator Good day, everyone, and welcome to today's Senseonics Fourth Quarter and Full Year ...